Deprescribing in older people

Maturitas

Volumn 91, Issue , 2016, Pages 115-134

  Page, Amy Theresa ^a   Potter, Kathleen ^a   Clifford, Rhonda ^a   Etherton Beer, Christopher ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Deprescribing; Inappropriate prescribing; Older adults; Polypharmacy

Indexed keywords

ADVERSE DRUG REACTION; AGED; AGING; DRUG INTERACTION; DRUG WITHDRAWAL; FOLLOW UP; FRAIL ELDERLY; GERIATRICS; HEALTH CARE; HUMAN; INAPPROPRIATE PRESCRIBING; POLYPHARMACY; PRESCRIPTION; PREVALENCE; REVIEW; RISK BENEFIT ANALYSIS; CHRONIC DISEASE; DEPRESCRIPTION; ELDERLY CARE;

AGED; CHRONIC DISEASE; DEPRESCRIPTIONS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HEALTH SERVICES FOR THE AGED; HUMANS;

EID: 84978288633     PISSN: 03785122     EISSN: 18734111     Source Type: Journal    
DOI: 10.1016/j.maturitas.2016.06.006     Document Type: Review

References (133)

1. [1] Eckerblad, J., Theander, K., Ekdahl, A., Unosson, M., Wirehn, A.-B., Milberg, A., et al. Symptom burden in community-dwelling older people with multimorbidity: a cross-sectional study. BMC Geriatr., 15, 2015, 1.
2. [2] Fortin, M., Bravo, G., Hudon, C., Vanasse, A., Lapointe, L., Prevalence of multimorbidity among adults seen in family practice. Ann. Fam. Med. 3 (2005), 223–228.
3. [3] Brilleman, S.L., Salisbury, C., Comparing measures of multimorbidity to predict outcomes in primary care: a cross sectional study. Fam. Pract. 30 (2013), 172–178.
4. [4] Hanlon, J.T., Schmader, K.E., Ruby, C.M., Weinberger, M., Suboptimal prescribing in older inpatients and outpatients. J. Am. Geriatr. Soc. 49 (2001), 200–209.
5. [5] Salvi, F., Rossi, L., Lattanzio, F., Cherubini, A., Is polypharmacy an independent risk factor for adverse outcomes after an emergency department visit. Intern. Emerg. Med., 2016, 1–8.
6. [6] Cherubini, A., Corsonello, A., Lattanzio, F., Underprescription of beneficial medicines in older people: causes, consequences and prevention. Drugs Aging 29 (2012), 463–475.
7. [7] Scott, I., Jayathissa, S., Quality of drug prescribing in older patients: is there a problem and can we improve it. Intern. Med. J. 40 (2010), 7–18.
8. [8] Scott, I.A., Hilmer, S.N., Reeve, E., Potter, K., Couteur, D.L., Rigby, D., et al. Reducing inappropriate polypharmacy the process of deprescribing. JAMA Intern. Med. 175 (2015), 827–834.
9. [9] United Nations Department of Economic and Social Affairs Population Division, World Popul. Ageing, ST/ESA/SER.A/348 (2013).
10. [10] Fries, J.F., Bruce, B., Chakravarty, E., Compression of morbidity 1980–2011: a focused review of paradigms and progress. J. Aging Res., 2011, 2011, 261702.
11. [11] Steinman, M.A., Miao, Y., Boscardin, W.J., Komaiko, K.D., Schwartz, J.B., Prescribing quality in older veterans: a multifocal approach. J. Gen. Intern. Med. 29 (2014), 1379–1386.
12. [12] Hubbard, R.E., Peel, N.M., Scott, I.A., Martin, J.H., Smith, A., Pillans, P.I., et al. Polypharmacy among inpatients aged 70 years or older in Australia. Med. J. Aust. 202 (2015), 373–378.
13. [13] Guthrie, B., Makubate, B., Hernandez-Santiago, V., Dreischulte, T., The rising tide of polypharmacy and drug–drug interactions: population database analysis 1995–2010. BMC Med., 2015, 2015.
14. [14] Samoy, L.J., Zed, P.J., Wilbur, K., Balen, R.M., Abu-Laban, R.B., Roberts, M., Drug-related hospitalizations in a tertiary care internal medicine service of a Canadian hospital: A prospective study. Pharmacotherapy 26 (2006), 1578–1586.
15. [15] Gnjidic, D., Hilmer, S.N., Blyth, F.M., Naganathan, V., Waite, L., Seibel, M.J., et al. Polypharmacy cutoff and outcomes: Five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes. J. Clin. Epidemiol. 65 (2012), 989–995.
16. [16] Turner, J.P., Jamsen, K.M., Shakib, S., Singhal, N., Prowse, R., Bell, J.S., Polypharmacy cut-points in older people with cancer: how many medications are too many?. Supportive Care Cancer 24 (2016), 1831–1840.
17. [17] Huizer-Pajkos, A., Kane, A.E., Howlett, S.E., Mach, J., Mitchell, S.J., de Cabo, R., et al. Adverse geriatric outcomes secondary to polypharmacy in a mouse model: the influence of aging. J. Gerontol. Series A: Biol. Sci. Med. Sci., 2015, glv046.
18. [18] Hajjar, E.R., Cafiero, A.C., Hanlon, J.T., Polypharmacy in elderly patients. Am. J. Geriatric Pharmacother. 5 (2007), 345–351.
19. [19] Jokanovic, N., Tan, E.C.K., Dooley, M.J., Kirkpatrick, C.M., Bell, J.S., Prevalence and factors associated with polypharmacy in long-term care facilities: A systematic review. J. Am. Med. Dir. Assoc., 2015, e1-.e12.
20. [20] Gnjidic, D., Hilmer, S.N., Blyth, F.M., Naganathan, V., Cumming, R.G., Handelsman, D.J., et al. High-risk prescribing and incidence of frailty among older community-dwelling men. Clin. Pharmacol. Ther. 91 (2012), 521–528.
21. [21] Halczli, A., Woolley, A.B., Medication underdosing and underprescribing: Issues that may contribute to polypharmacy, poor outcomes. Formulary 48 (2013), 194–196.
22. [22] Van Den Heuvel, P.M.L., Maartje, L., Van Marum, R.J., Jansen, P.A.F., Polypharmacy and underprescribing in older adults: Rational underprescribing by general practitioners. J. Am. Geriatr. Soc. 59 (2011), 1750–1752.
23. [23] Barry, P.J., Gallagher, P., Ryan, C., O'Mahony, D., START (screening tool to alert doctors to the right treatment) - An evidence-based screening tool to detect prescribing omissions in elderly patients. Age Ageing 36 (2007), 632–638.
24. [24] Maher, R.L., Hanlon, J., Hajjar, E.R., Clinical consequences of polypharmacy in elderly. Expert Opin. Drug Saf. 13 (2014), 57–65.
25. [25] Tjia, J., Velten, S.J., Parsons, C., Valluri, S., Briesacher, B.A., Studies to reduce unnecessary medication use in frail older adults: A systematic review. Drugs & Aging 30 (2013), 285–307.
26. [26] Rossi, M.I., Young, A., Maher, R., Rodriguez, K.L., Appelt, C.J., Perera, S., et al. Polypharmacy and health beliefs in older outpatients. Am. J. Geriatric Pharmacother. 5 (2007), 317–323.
27. [27] Rochon, P.A., Gurwitz, J.H., Optimising drug treatment for elderly people: The prescribing cascade. British Med. J. 315 (1997), 1096–1099.
28. [28] Hilmer, S.N., Gnjidic, D., The Effects of Polypharmacy in Older Adults. Clin. Pharmacol. Ther. 85 (2009), 86–88.
29. [29] Gill, S.S., Mamdani, M., Naglie, G., Streiner, D.L., Bronskill, S.E., Kopp, A., et al. A prescribing cascade involving cholinesterase inhibitors and anticholinergic drugs. Arch. Intern. Med. 165 (2005), 808–813.
30. [30] Vegter, S., De Jong-Van Den Berg, L.T.W., Misdiagnosis and mistreatment of a common side-effect - Angiotensin-converting enzyme inhibitor-induced cough. British J. Clin. Pharmacol. 69 (2010), 200–203.
31. [31] Ryan, C., O'Mahony, D., O'Donovan, D.Ó, O'Grady, E., Weedle, P., Kennedy, J., et al. A comparison of the application of STOPP/START to patients' drug lists with and without clinical information. Int. J. Clin. Pharm. 35 (2013), 230–235.
32. [32] Dalleur, O., Boland, B., Losseau, C., Henrard, S., Wouters, D., Speybroeck, N., et al. Reduction of potentially inappropriate medications using the STOPP criteria in frail older inpatients: A randomised controlled study. Drugs & Aging 31 (2014), 291–298.
33. [33] Gnjidic, D., Le Couteur, D.G., Pearson, S.A., McLachlan, A.J., Viney, R., Hilmer, S.N., et al. High risk prescribing in older adults: Prevalence, clinical and economic implications and potential for intervention at the population level. BMC Public Health, 2013, 13.
34. [34] Hilmer, S.N., Mager, D.E., Simonsick, E.M., Cao, Y., Ling, S.M., Windham, B.G., et al. A drug burden index to define the functional burden of medications in older people. Arch. Intern. Med. 167 (2007), 781–787.
35. [35] Ryan, C., O'Mahony, D., Kennedy, J., Weedle, P., Cottrell, E., Heffernan, M., et al. Potentially inappropriate prescribing in older residents in Irish nursing homes. Age and Ageing 42 (2013), 116–120.
36. [36] Marcum, Z.A., Pugh, M.J.V., Amuan, M.E., Aspinall, S.L., Handler, S.M., Ruby, C.M., et al. Prevalence of potentially preventable unplanned hospitalizations caused by therapeutic failures and adverse drug withdrawal events among older veterans. J. Gerontol. Series A-Biol. Sci. Med. Sci. 67 (2012), 867–874.
37. [37] The American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. Journal of the American Geriatrics Society. (2015) 63, 2227–46.
38. [38] Renom-Guiteras, A., Meyer, G., Thürmann, P.A., The EU(7)-PIM list: A list of potentially inappropriate medications for older people consented by experts from seven European countries. Eur. J. Clin. Pharmacol. 71 (2015), 861–875.
39. [39] O'Mahony, D., O'Sullivan, D., Byrne, S., O'Connor, M.N., Ryan, C., Gallagher, P., STOPP/START criteria for potentially inappropriate prescribing in older people: Version 2. Age and Ageing 44 (2015), 213–218.
40. [40] Mann, E., Böhmdorfer, B., Frühwald, T., Roller-Wirnsberger, R.E., Dovjak, P., Dückelmann-Hofer, C., et al. Potentially inappropriate medication in geriatric patients: the Austrian consensus panel list. Wien. Klin. Wochenschr. 124 (2012), 160–169.
41. [41] Chang, C.B., Yang, S.Y., Lai, H.Y., Wu, R.S., Liu, H.C., Hsu, H.Y., et al. Using published criteria to develop a list of potentially inappropriate medications for elderly patients in Taiwan. Pharmacoepidemiol. Drug Saf. 21 (2012), 1269–1279.
42. [42] Maio, V., Canale, S.D., Abouzaid, S., Using explicit criteria to evaluate the quality of prescribing in elderly Italian outpatients: a cohort study. J. Clin. Pharm. Ther. 35 (2010), 219–229.
43. [43] Kim, D.S., Heo, S.I., Lee, S.H., Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method. Healthcare Inf. Res. 16 (2010), 231–252.
44. [44] Holt, S., Schmiedl, S., Thürmann, P.A., Potentially inappropriate medications in the elderly: The PRISCUS list. Deutsches Arzteblatt 107 (2010), 543–551.
45. [45] Rognstad, S., Brekke, M., Fetveit, A., Spigset, O., Wyller, T.B., Straand, J., The norwegian general practice (NORGEP) criteria for assessing potentially inappropriate prescriptions to elderly patients. Scand. J. Prim. Health Care 27 (2009), 153–159.
46. [46] Basger, B.J., Chen, T.F., Moles, R.J., Validation of prescribing appropriateness criteria for older Australians using the RAND/UCLA appropriateness method. BMJ Open, 2012, 2.
47. [47] Winit-Watjana, W., Sakulrat, P., Kespichayawattana, J., Criteria for high-risk medication use in Thai older patients. Arch. Gerontol. Geriatr. 47 (2008), 35–51.
48. [48] Laroche, M.L., Charmes, J.P., Merle, L., Potentially inappropriate medications in the elderly: A French consensus panel list. Eur. J. Clin. Pharmacol. 63 (2007), 725–731.
49. [49] Rancourt, C., Moisan, J., Baillargeon, L., Verreault, R., Laurin, D., Grégoire, J.-P., Potentially inappropriate prescriptions for older patients in long-term care. BMC Geriatr., 4, 2004, 9.
50. [50] Naugler, C.T., Brymer, C., Stolee, P., Arcese, Z.A., Development and validation of an improving prescribing in the elderly tool. Can. J. Clin. Pharmacol. 7 (2000), 103–107.
51. [51] McLeod, P.J., Huang, A.R., Tamblyn, R.M., Gayton, D.C., Defining inappropriate practices in prescribing for elderly people: A national consensus panel. CMAJ 156 (1997), 385–391.
52. [52] Zhan, C., Sangl, J., Bierman, A.S., Miller, M.R., Friedman, B., Wickizer, S.W., et al. Potentially inappropriate medication use in the community-dwelling elderly: Findings from the 1996 Medical Expenditure Panel Survey. J. Am. Med. Assoc. 286 (2001), 2823–2829.
53. [53] Garfinkel, D., Mangin, D., Feasibility study of a systematic approach for discontinuation of multiple medications in older adults: Addressing polypharmacy. Arch. Intern. Med. 170 (2010), 1648–1654.
54. [54] Garfinkel, D., Zur-Gil, S., Ben-Israel, J., The war against polypharmacy: A new cost-effective geriatric-positive approach for improving drug therapy in disabled elderly people. Isr. Med. Assoc. J. 9 (2007), 430–434.
55. [55] Potter, K., Flicker, L., Page, A., Etherton-Beer, C., Deprescribing in frail older people: a randomized controlled trial. PLOS One, 11, 2016, e0149984.
56. [56] C.P. Etherton-Beer, Opti-Med: A Randomised Controlled Trial of Deprescribing to Optimise Health Outcomes for Frail Older People Australian New Zealand Clinical Trials Registry 4/11/2013 ed.
57. [57] McKean, M., Pillans, P.I., Scott, I.A., A medication review and deprescribing method for hospitalised older patients receiving multiple medications. Intern. Med. J., 2015.
58. [58] Drenth-van Maanen, A.C., van Marum, R.J., Knol, W., van der Linden, C.M., Jansen, P.A., Prescribing optimization method for improving prescribing in elderly patients receiving polypharmacy. Drugs & Aging 26 (2009), 687–701.
59. [59] Page, A.T., Etherton-Beer, C.D., Clifford, R.M., Burrows, S., Eames, M., Potter, K., Deprescribing in frail older people—Do doctors and pharmacists agree?. Res. Soc. Admin. Pharm. 12 (2016), 438–449.
60. [60] Scott, I.A., Le Couteur, D.G., Physicians need to take the lead in deprescribing. Intern. Med. J. 45 (2015), 352–356.
61. [61] Anderson, K., Foster, M.M., Freeman, C.R., Scott, I.A., A multifaceted intervention to reduce inappropriate polypharmacy in primary care: research co-creation opportunities in a pilot study. Med. J. Aust. 204 (2016), S41–S44.
62. [62] Scott, I.A., Gray, L.C., Martin, J.H., Pillans, P.I., Mitchell, C.A., Deciding when to stop: Towards evidence-based deprescribing of drugs in older populations. Evidence-Based Med. 18 (2013), 121–124.
63. [63] Scott, I.A., Gray, L.C., Martin, J.H., Mitchell, C.A., Effects of a drug minimization guide on prescribing intentions in elderly persons with polypharmacy. Drugs & Aging 29 (2012), 659–667.
64. [64] Haque, R., ARMOR: a tool to evaluate polypharmacy in elderly persons. Ann. Long-Term Care 17 (2009), 26–30.
65. [65] Hanlon, J.T., Schmader, K.E., Samsa, G.P., Weinberger, M., Uttech, K.M., Lewis, I.K., et al. A method for assessing drug therapy appropriateness. J. Clin. Epidemiol. 45 (1992), 1045–1051.
66. [66] Hanlon, J.T., Schmader, K.E., The medication appropriateness index at 20: where it started, where it has been, and where it may be going. Drugs & Aging 30 (2013), 893–900.
67. [67] Poudel, A., Hubbard, R.E., Nissen, L., Mitchell, C., Frailty: A key indicator to minimize inappropriate medication in older people. QJM 106 (2013), 969–975.
68. [68] Rockwood, K., Mitnitski, A., Frailty in relation to the accumulation of deficits. J. Gerontol. Series A: Biol. Sci. Med. Sci. 62 (2007), 722–727.
69. [69] Fried, L.P., Tangen, C.M., Walston, J., Newman, A.B., Hirsch, C., Gottdiener, J., et al. Frailty in older adults: Evidence for a phenotype. J. Gerontol. - Series A Biol. Sci. Med. Sci. 56 (2001), M146–M156.
70. [70] Kennedy-Martin, T., Curtis, S., Faries, D., Robinson, S., Johnston, J., A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results. Trials, 2015, 16.
71. [71] Van Spall, H.G.C., Toren, A., Kiss, A., Fowler, R.A., Eligibility criteria of randomized controlled trials published in high-impact general medical journals: A systematic sampling review. J. Am. Med. Assoc. 297 (2007), 1233–1240.
72. [72] Scher, K.S., Hurria, A., Under-representation of older adults in cancer registration trials: known problem, little progress. J. Clin. Oncol. 30 (2012), 2036–2038.
73. [73] Anderson, K., Stowasser, D., Freeman, C., Scott, I., Prescriber barriers and enablers to minimising potentially inappropriate medications in adults: A systematic review and thematic synthesis. BMJ Open, 2014, 4.
74. [74] Le Couteur, D.G., McLachlan, A.J., De Cabo, R., Aging, drugs, and drug metabolism. J. Gerontol. - Series A Bio. Sci. Med. Sci., 2012, 137–139.
75. [75] Hilmer, S.N., McLachlan, A.J., Le Couteur, D.G., Clinical pharmacology in the geriatric patient. Fundam. Clin. Pharmacol. 21 (2007), 217–230.
76. [76] Hilmer, S.N., ADME-tox issues for the elderly. Expert Opin. Drug Metabol. Toxicol. 4 (2008), 1321–1331.
77. [77] McLachlan, A.J., Pont, L.G., Drug metabolism in older people - A key consideration in achieving optimal outcomes with medicines. J. Gerontol. - Series A Biol. Sci. Med. Sci., 2012, 175–180.
78. [78] McLachlan, A.J., Hilmer, S.N., Le Couteur, D.G., Variability in response to medicines in older people: Phenotypic and genotypic factors. Clin. Pharmacol. Ther. 85 (2009), 431–433.
79. [79] Garfinkel, D., Ilhan, B., Bahat, G., Routine deprescribing of chronic medications to combat polypharmacy. Ther. Adv. Drug Saf. 6 (2015), 212–233.
80. [80] Fortin, M., Soubhi, H., Hudon, C., Bayliss, E.A., Van Den Akker, M., Multimorbidity's many challenges. British Med. J. 334 (2007), 1016–1017.
81. [81] Cahir, C., Bennett, K., Teljeur, C., Fahey, T., Potentially inappropriate prescribing and adverse health outcomes in community dwelling older patients. British J. Clin. Pharmacol., 77, 2014, 20.
82. [82] Vitry, A.I., Zhang, Y., Quality of Australian clinical guidelines and relevance to the care of older people with multiple comorbid conditions. Med. J. Aust. 189 (2008), 360–365.
83. [83] Boyd, C.M., Darer, J., Boult, C., Fried, L.P., Boult, L., Wu, A.W., Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases - Implications for pay for performance. JAMA J. Am. Med. Assoc. 294 (2005), 716–724.
84. [84] Jamsen, K.M., Bell, J.S., Hilmer, S.N., Kirkpatrick, C.M.J., Ilomäki, J., Le Couteur, D., et al. Effects of changes in number of medications and drug burden index exposure on transitions between frailty states and death: The concord health and ageing in men project cohort study. J. Am. Geriatr. Soc. 64 (2016), 89–95.
85. [85] Kuijpers, M.A.J., van Marum, R.J., Egberts, A.C.G., Jansen, P.A.F., Grp, O.S., Relationship between polypharmacy and underprescribing. British J. Clin. Pharmacol. 65 (2008), 130–133.
86. [86] Reeve, E., Gnjidic, D., Long, J., Hilmer, S., A systematic review of the emerging definition of 'deprescribing' with network analysis: Implications for future research and clinical practice. British J. Clin. Pharmacol. 80 (2015), 1254–1268.
87. [87] Qi, K., Reeve, E., Hilmer, S.N., Pearson, S.A., Matthews, S., Gnjidic, D., Older peoples’ attitudes regarding polypharmacy, statin use and willingness to have statins deprescribed in Australia. Int. Journal of Clin. Pharm. 37 (2015), 949–957.
88. [88] Reeve, E., To, J., Hendrix, I., Shakib, S., Roberts, M.S., Wiese, M.D., Patient barriers to and enablers of deprescribing: A systematic review. Drugs & Aging 30 (2013), 793–807.
89. [89] Page, A.T., Etherton-Beer, C.D., Clifford, R.M., Burrows, S., Eames, M., Potter, K., Deprescribing in frail older people—Do doctors and pharmacists agree?. Res. Soc. Adm. Pharm., 2015.
90. [90] Page, A.T., Clifford, R.M., Potter, K., Schwartz, D., Etherton‐Beer, C.D., The feasibility and the effect of deprescribing in older adults on mortality and health: A systematic review. British J. Clin. Pharmacol., 2016.
91. [91] Weber, V., White, A., McIivried, R., An electronic medical record (EMR)-Based intervention to reduce polypharmacy and falls in an ambulatory rural elderly population. J. Gen. Intern. Med. 23 (2008), 399–404.
92. [92] Gallagher, P.F., O'Connor, M.N., O'Mahony, D., Prevention of Potentially Inappropriate Prescribing for Elderly Patients: A Randomized Controlled Trial Using STOPP/START Criteria. Clin. Pharmacol. Ther., 2011.
93. [93] Allard, J., Hebert, R., Asselin, J., Voyer, L., Efficacy of a clinical medication review on the number of potentially inappropriate prescriptions prescribed for community-dwelling elderly people. Can. Med. Assoc. J. 164 (2001), 1291–1296.
94. [94] Gnjidic, D., Le Couteur, D.G., Abernethy, D.R., Hilmer, S.N., A pilot randomized clinical trial utilizing the drug burden index to reduce exposure to anticholinergic and sedative medications in older people. Ann. Pharmacother. 44 (2010), 1725–1732.
95. [95] García-Gollarte, F., Baleriola-Júlvez, J., Ferrero-López, I., Cuenllas-Díaz Á, Cruz-Jentoft, A.J., An educational intervention on drug use in nursing homes improves health outcomes resource utilization and reduces inappropriate drug prescription. J. Am. Med. Dir. Assoc. 15 (2014), 885–891.
96. [96] Pitkala, K.H., Juola, A.-L., Kautiainen, H., Soini, H., Finne-Soveri, U.H., Bell, J.S., et al. Education to Reduce Potentially Harmful Medication Use Among Residents of Assisted Living Facilities: A Randomized Controlled Trial. J. Am. Med. Dir. Assoc. 15 (2014), 892–898.
97. [97] Moonen, J.E.F., Foster-Dingley, J.C., Ce Ruijter, W., Van Der Grond, J., Bertens, A.S., Van Buchem, M.A., et al. Effect of discontinuation of antihypertensive treatment in elderly people on cognitive functioning-the DANTE Study Leiden: A randomized clinical trial. JAMA Intern. Med. 175 (2015), 1622–1630.
98. [98] Moonen, J.E.F., Foster-Dingley, J.C., De Ruijter, W., Van Der Grond, J., De Craen, A.J.M., Van Der Mast, R.C., Effect of discontinuation of antihypertensive medication on orthostatic hypotension in older persons with mild cognitive impairment: The DANTE Study Leiden. Age and ageing 45 (2016), 249–255.
99. [99] Yedidya Idit, Netzer Adi, Vaduganathan Muthiah, Solodky Alejandro, Kornowski Ran, Lev Eli I., Clopidogrel tapering as a strategy to attenuate platelet rebound phenomenon in patients with bare-metal stents, J. Thromb.Thrombolysis (2012) 33, 16–21.
100. [100] Patel, M.R., Hellkamp, A.S., Lokhnygina, Y., Piccini, J.P., Zhang, Z., Mohanty, S., et al. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: Analysis from the ROCKET AF trial (Rivaroxaban once-daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation). J. Am. Coll. Cardiol. 61 (2013), 651–658.
101. [101] Jondeau, G., Neuder, Y., Eicher, J.-C., Jourdain, P., Fauveau, E., Galinier, M., et al. B-CONVINCED: Beta-blocker CONtinuation Vs. INterruption in patients with Congestive heart failure hospitalizED for a decompensation episode. Eur. Heart J. 30 (2009), 2186–2192.
102. [102] van Kraaij, D.J.W., Jansen, R., Bouwels, L.H.R., Gribnau, F.W.J., Hoefnagels, W.H.L., Furosemide withdrawal in elderly heart failure patients with preserved left ventricular systolic function. Am. J. Cardiol. 85 (2000), 1461–1466.
103. [103] George, J., Kitzis, I., Zandorf, D., Golovner, M., Shapira, I., Laniado, S., et al. Safety of nitrate withdrawal in angina-free and hemodynamically stable patients with coronary artery disease. Chest 124 (2003), 1652–1657.
104. [104] Kutner Jean S., Blatchford Patrick, Taylor Don, Ritchie Christine, Bull Janet, Fairclough Diane, et al. Safety and Benefit of Discontinuing Statin Therapy in the Setting of Advanced, Life-Limiting IllnessA Randomized Clinical Trial, JAMA Intern. Med., (2015).
105. [105] Lin, V.C.-H., Liao, C.-H., Kuo, H.-C., Progression of lower urinary tract symptoms after discontinuation of 1 medication from 2-year combined alpha-blocker and 5-alpha—Reductase inhibitor therapy for benign prostatic hyperplasia in men—A randomized multicenter study. Urology 83 (2014), 416–421.
106. [106] Cibere, J., Kopec, J.A., Thorne, A., Singer, J., Canvin, J., Robinson, D.B., et al. Randomized, double-blind, placebo-controlled glucosamine discontinuation trial in knee osteoarthritis. Arthritis & Rheumatism-Arthritis Care & Res. 51 (2004), 738–745.
107. [107] Black, D.M., Reid, I.R., Boonen, S., Bucci-Rechtweg, C., Cauley, J.A., Cosman, F., et al. The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J. Bone Mine. Res. 27 (2012), 243–254.
108. [108] Black, D.M., Schwartz, A.V., Ensrud, K.E., Cauley, J.A., Levis, S., Quandt, S.A., et al. Effects of continuing or stopping alendronate after 5 years of treatment—The Fracture Intervention Trial long-term extension (FLEX): A randomized trial. JAMA J. Am. Med. Assoc. 296 (2006), 2927–2938.
109. [109] Dawson-Hughes, B., Harris, S.S., Krall, E.A., Dallal, G.E., Effect of withdrawal of calcium and vitamin D supplements on bone mass in elderly men and women. Am. J. Clin. Nutr. 72 (2000), 745–750.
110. [110] Gallagher, J.C., Rapuri, P.B., Haynatzki, G., Detter, J.R., Effect of discontinuation of estrogen, calcitriol, and the combination of both on bone density and bone markers. J. Clin. Endocrinol. Metab. 87 (2002), 4914–4923.
111. [111] Tse, W., Frisina, P.G., Haelbit, T.D., Gracies, J.M., Liang, L., Tarshish, C., et al. The effects of withdrawal of dopaminergic medication in nursing home patients with advanced parkinsonism. J. Am. Med. Dir. Assoc. 9 (2008), 670–675.
112. [112] Bergh, S., Selbaek, G., Engedal, K., Discontinuation of antidepressants in people with dementia and neuropsychiatric symptoms (DESEP study): double blind, randomised, parallel group, placebo controlled trial. British Med. J., 344, 2012, 12.
113. [113] Ulfvarson, J., Adami, J., Wredling, R., Kjellman, B., Reilly, M., Von Bahr, C., Controlled withdrawal of selective serotonin reuptake inhibitor drugs in elderly patients in nursing homes with no indication of depression. Eur. J. Clin. Pharmacol. 59 (2003), 735–740.
114. [114] Devanand, D.P., Mintzer, J., Schultz, S.K., Andrews, H.F., Sultzer, D.L., de la Pena, D., et al. Relapse risk after discontinuation of risperidone in Alzheimer's disease. N. Engl. J. Med. 367 (2012), 1497–1507.
115. [115] Devanand, D.P., Pelton, G.H., Cunqueiro, K., Sackeim, H.A., Marder, K., A 6-month, randomized, double-blind, placebo-controlled pilot discontinuation trial following response to haloperidol treatment of psychosis and agitation in Alzheimer's disease. Int. J. Geriatr. Psychiatry 26 (2011), 937–943.
116. [116] Ballard, C., Hanney, M.L., Theodoulou, M., Douglas, S., McShane, R., Kossakowski, K., et al. The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial. Lancet Neurol. 8 (2009), 151–157.
117. [117] Ballard, C., Lana, M.M., Theodoulou, M., Douglas, S., McShane, R., Jacoby, R., et al. A randomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (The DART-AD Trial). PLoS Med. 5 (2008), 0587–0599.
118. [118] Ballard, C.G., Thomas, A., Fossey, J., Lee, L., Jacoby, R., Lana, M.M., et al. A 3-month, randomized, placebo-controlled, neuroleptic discontinuation study in 100 people with dementia: The neuropsychiatric inventory median cutoff is a predictor of clinical outcome. J. Clin. Psychiatry 65 (2004), 114–119.
119. [119] Ruths, S., Straand, J., Nygaard, H.A., Bjorvatn, B., Pallesen, S., Effect of antipsychotic withdrawal on behavior and sleep/wake activity in nursing home residents with dementia: A randomized, placebo-controlled, double-blinded study: The Bergen district nursing home study. J. Am. Geriatr. Soc. 52 (2004), 1737–1743.
120. [120] Van Reekum, R., Clarke, D., Conn, D., Herrmann, N., Eryavec, G., Cohen, T., et al. A randomized, placebo-controlled trial of the discontinuation of long-term antipsychotics in dementia. Int. Psychogeriatr. 14 (2002), 197–210.
121. [121] Tannenbaum, C., Martin P2 Tamblyn, R., Benedetti, A., Ahmed, S., Reduction of inappropriate benzodiazepine prescriptions among older adults through direct patient education: the EMPOWER cluster randomized trial. JAMA Intern. Med. 174 (2014), 890–898.
122. [122] Curran, H.V., Collins, R., Fletcher, S., Kee, S.C.Y., Woods, B., Iliffe, S., Older adults and withdrawal from benzodiazepine hypnotics in general practice: Effects on cognitive function, sleep, mood and quality of life. Psychol. Med. 33 (2003), 1223–1237.
123. [123] Petrovic, M., Pevernagie, D., Mariman, A., Van Maele, G., Afschrift, M., Fast withdrawal from benzodiazepines in geriatric inpatients: a randomised double-blind, placebo-controlled trial. Eur. J. Clin. Pharmacol. 57 (2002), 759–764.
124. [124] Gaudig, M., Richarz, U., Han, J., Van Baelen, B., Schauble, B., Effects of galantamine in alzheimer's disease: double-blind withdrawal studies evaluating sustained versus interrupted treatment. Curr. Alzheimer Res. 8 (2011), 771–780.
125. [125] Scarpini, E., Bruno, G., Zappala, G., Adami, M., Richarz, U., Gaudig, M., et al. Cessation versus continuation of galantamine treatment after 12 months of therapy in patients with Alzheimer's disease: a randomized, double blind, placebo controlled withdrawal trial. J. Alzheimers Dis. 26 (2011), 211–220.
126. [126] Rice, K.L., Rubins, J.B., Lebahn, F., Parenti, C.M., Duane, P.G., Kuskowski, M., et al. Withdrawal of chronic systemic corticosteroids in patients with COPD—A randomized trial. Am. J. Respir. Crit. Care Med. 162 (2000), 174–178.
127. [127] Borrill, Z., Roy, K., Kolsum, U., Southworth, T., Vestbo, J., Singh, D., Seretide withdrawal increases airway inflammation in moderate COPD patients. Eur. J. Clin. Pharmacol. 65 (2009), 1165–1166.
128. [128] Choudhury, A.B., Dawson, C.M., Kilvington, H.E., Eldridge, S., James, W.Y., Wedzicha, J.A., et al. Withdrawal of inhaled corticosteroids in people with COPD in primary care: A randomised controlled trial. Respir. Res., 2007, 8.
129. [129] O'Brien, A., Russo-Magno, P., Karki, A., Hiranniramol, S., Hardin, M., Kaszuba, M., et al. Effects of withdrawal of inhaled steroids in men with severe irreversible airflow obstruction. Am. J. Respir. Crit. Care Med. 164 (2001), 365–371.
130. [130] Bain, K.T., Holmes, H.M., Beers, M.H., Maio, V., Handler, S.M., Pauker, S.G., Discontinuing medications: A novel approach for revising the prescribing stage of the medication-use process. J. Am. Geriatr. Soc. 56 (2008), 1946–1952.
131. [131] Gerety, M.B., Cornell, J.E., Plichta, D.T., Eimer, M., Adverse events related to drugs and drug withdrawal in nursing-home residents. J. Am. Geriatr. Soc. 41 (1993), 1326–1332.
132. [132] Graves, T., Hanlon, J.T., Schmaler, K.E., Landsman, P.B., Samsa, G.P., Pieper, C.F., et al. Adverse events after discontinuing medications in elderly outpatients. Arch. Intern. Med. 157 (1997), 2205–2210.
133. [133] Reeve, E., Shakib, S., Hendrix, I., Roberts, M.S., Wiese, M.D., The benefits and harms of deprescribing. Med. J. Aust., 2014, 201.